Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $37.00

Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its price objective increased by Credit Suisse Group from $36.00 to $37.00 in a research report sent to investors on Friday morning, Benzinga reports. Credit Suisse Group currently has a neutral rating on the stock. A number of other brokerages also recently issued reports on KYMR. Raymond James […]

Related Keywords

Hong Kong ,Zurcher Kantonalbank Zurich Cantonalbank ,Raymond James ,Credit Suisse Group ,Kymera Therapeutics Inc ,Exchange Traded Concepts ,Hong Kong Ltd ,Advisors Asset Management Inc ,Kymera Therapeutics ,Free Report ,Suisse Group ,Moderate Buy ,Therapeutics Stock Down ,Get Free Report ,Kong Ltd ,Asset Management ,Kantonalbank Zurich Cantonalbank ,Kymera Therapeutics Daily ,Nasdaq Kymr ,Kymr ,Medical ,Boost Price Target ,Credit Suisse Group Ag ,